期刊文献+

CTNNA1基因启动子区异常甲基化与急性髓系白血病的相关性分析 被引量:3

Correlation between abnormal methylation of CTNNA1 gene promoter region with acute myeloid leukemia
下载PDF
导出
摘要 目的研究CTNNA1基因启动子区异常甲基化与急性髓系白血病(AML)发生的相关性。方法选取180例AML患者骨髓标本及24例健康供者骨髓标本,通过甲基化特异性PCR方法(MS-PCR)进行CTNNA1基因启动子区异常甲基化阳性率进行检测,提取基因组DNA,设计硫化测序PCR(BS-PCR)引物及甲基化特异性PCR(MS-PCR)引物,进行PCR扩增及测序分析。结果 5例健康者标本及5例AML患者标本DNA经硫化且BS-PCR测序分析,其健康者标本甲基化率分别为1.5%、1.0%、1.0%、1.5%、1.0%,而AML患者CTNNA1甲基化率分别为92.0%、78.5%、86.0%、56.0%、90.0%,远远高于健康供者。MS-PCR分析结果显示,CTNNA1基因在24例健康人中呈完全非甲基化状态,在180例AML患者中其甲基化阳性率为37.2%(P<0.05)。结论 CTNNA1基因启动子区异常甲基化可能参与AML的发生,为疾病的早期监测提供分子理论依据。 Objective To study the correlation between the aberrant methylation of CTNNA1 gene promoter region with acute myeloid leukemia(AML).Methods The bone marrow samples from 180 patients with AML and 24 healthy donors were collected in this study.The methylation-specific polymerase chain reaction(MS-PCR)method was adopted to detect the positive rate of aberrant methylation in CTNNA1 gene promoter region.The genome DNA was extracted,and the primers of sulfuration sequencing PCR(BS-PCR)and MS-PCR were designed to perform the PCR amplification and sequencing analysis.Results DNA in 5healthy samples and 5AML samples was vulcanized and sequenced by BS-PCR,the methylation rates in the healthy samples were 1.5%,1.0%,1.0%,1.5% and 1.0%respectively,while the methylation rates of the CTNNA1 gene in AML patients were 92.0%,78.5%,86.0%,56.0%and 90.0%respectively,which were much higher than the healthy donors.The MS-PCR analysis results showed that the CTNNA1 gene presented as the unmethylated status in healtyh donors,the methylation rate in 180 AML patients was 37.2%(P〈0.05).Conclusion The aberrant methylation of the CTNNA1 gene promoter region is perhaps involved in the occurrence of AML,which provides the molecular theoretical basis of early monitoring disease.
作者 刘莉 李绵洋
出处 《检验医学与临床》 CAS 2016年第7期907-908,共2页 Laboratory Medicine and Clinic
关键词 CTNNA1基因 异常甲基化 急性髓系白血病 CTNNA1gene aberrant methylation acute myeloid leukemia
  • 相关文献

参考文献12

  • 1Herman JG,Baylin SB. Gene silencing in cancer in associ- ation with promoter hypermethylation[J]. N Engl J Med, 2003,349 (21) : 2042-2054.
  • 2Segura-Pacheco B, Perez-Cardenas E, Taja-Chayeb L, et al. Global DNA hypermethylation-associated cancer chemothera- py resistance and its reversion with the demethylating agent hydralazine[J]. J Transl Med,2006,4(8) : t-13.
  • 3Cui X, Wakai T, Shirai Y, et ah Arsenic trioxide inhibits DNA methyltransferase and restores methylation-silenced genes in human liver cancer cells[J]. Hum Pathol, 2006, 37 (3) : 298-311.
  • 4Liu TX,Becker MW,Jelinek J, et ah Chromosome 5q de- letion and epigenetic suppression of the gene encoding al- pha-eatenin (CTNNA1) in myeloid cell transformation [J]. Nat Meal,2007,13(1):78-83.
  • 5Fu CT,Zhu KY,Mi JQ,et ah An evolutionarily conserved PTEN-C/EBPalpha-CTNNA1 axis controls myeloid de- velopment ai~d transformation[j ]. Blood, 2010,115 (23) : 4715-4724.
  • 6Yuan H, Zhou J, Deng M, et al. "Sumoylation of CCAAT/ enhancer-binding protein ~ promotes the biased primitive hematopoiesis of zebrafish [J ]. Blood, 2011, 117 ( 26 ) : 7014-7020.
  • 7Vanpoucke G, Nollet F, Tejpar S, et ah The human alpha- Ecatenin gene CTNNA1 :mutati0nal analysis and rare oc- currence of a truncated splice variant. Biochim[J]. Bio- phys Acta,2002,12,1574(3) :262-268.
  • 8Vasioukhin V, Bauer C, Degenstein L. Hyperproliieration and defects in epithelial polarity upon conditional ablation of alpha-catenin in skin[J]. Cell, 2001,23,104 (4) : 605- 617.
  • 9Fairman J,Chumakov I,Chinauh AC. Physical mapping of the minimal region of loss in 5q-chromosome. Proc[J]. Proc Natl Acad Sci U S A,1995,92(16)~7406-7410.
  • 10Issa JP, Gareia-Manero G,Giles FJ, et ah Phase 1 Study of low-dose prolonged exposure schedules of the hypometh- ylating agent 5-aza-2-deoxycytidine (decitabine) in hema- topoietic malignancies ['J]. Blood, 2004, 103 ( 5 ) ~ 1635- 1640.

同被引文献35

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部